KRAS and pancreatic intraductal papillary-mucinous neoplasm: In the pancreatic juice of patients with IPMN, current literature indicates a positive detection rate ranging from 39% to 62% for KRAS and 31% to 65% for GNAS mutations [29, 35, 36, 37, 38].